Status:
COMPLETED
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
Brief Summary
The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as deter...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of unresectable intermediate stage hepatocellular carcinoma (BCLC-B) for whom the decision has been taken by the investigator to prescribe Nexavar (the BCLC intermediate stage (BCLC-B) consists of Child-Pugh A and B patients with large/multifocal HCC who do not have cancer related symptoms, macrovascular invasion or extrahepatic spread).
Exclusion
- \- Prior targeted therapy for hepatocellular carcinoma.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01908322
Start Date
August 1 2013
End Date
September 1 2015
Last Update
November 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Germany